Skip to content

Study · Not a test of the peptide alone · 2012

2 results

The influence of AT1002 on the nasal absorption of molecular weight markers and therapeutic agents when co-administered with bioadhesive polymers and an AT1002 antagonist, AT1001.

Song KH, Eddington ND

The Journal of pharmacy and pharmacology21 Nov 2011Cited by 7 (Europe PMC)

PMID22150669 (opens in a new tab)DOI10.1111/j.2042-7158.2011.01381.x (opens in a new tab)PepBankPUB-22150669
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Larazotide.

  1. 01AnimalNot a test of Larazotide aloneAnimal study (in vivo)Mechanism

    In rats, AT1001 pretreatment antagonized the zonulin receptor.

    In plain wordsIn rats, AT1001 pretreatment blocked the zonulin receptor.

    Peptide
    Larazotide
    Outcome
    Not applicableZonulin receptor antagonism
    Study

    ratn: not reported in source

    Sprague-Dawley rats receiving nasal AT1002/inulin
    Comparator
    AT1002 without AT1001 pretreatment
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Pre-treatment with AT1001 antagonized the zonulin receptor and significantly minimized the permeation-enhancing effect of AT1002.
    2 context sentences
    Summary · context
    The bioadhesive polymers, carrageenan and Na-CMC, were prepared with AT1002 to examine the permeation-enhancing effect of AT1002 on the nasal absorption of inulin, calcitonin and saquinavir after nasal administration to Sprague-Dawley rats.
    Summary · context
    To examine this zonulin antagonist, AT1001, was administered 30 min prior to dosing with an AT1002/inulin solution and blood samples were collected over a 6-hour period.

    In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Larazotide.

  2. 02AnimalNot a test of Larazotide aloneAnimal study (in vivo)Mechanism

    In rats, AT1001 pretreatment significantly reduced the permeation-enhancing effect of AT1002.

    In plain wordsIn rats, AT1001 pretreatment reduced AT1002-induced permeation enhancement compared with AT1002 without AT1001 pretreatment.

    Peptide
    Larazotide
    Outcome
    DecreaseAT1002 permeation enhancement
    Study

    ratn: not reported in source

    Sprague-Dawley rats receiving nasal AT1002/inulin
    Comparator
    AT1002 without AT1001 pretreatment
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Pre-treatment with AT1001 antagonized the zonulin receptor and significantly minimized the permeation-enhancing effect of AT1002.
    2 context sentences
    Summary · context
    The bioadhesive polymers, carrageenan and Na-CMC, were prepared with AT1002 to examine the permeation-enhancing effect of AT1002 on the nasal absorption of inulin, calcitonin and saquinavir after nasal administration to Sprague-Dawley rats.
    Summary · context
    To examine this zonulin antagonist, AT1001, was administered 30 min prior to dosing with an AT1002/inulin solution and blood samples were collected over a 6-hour period.

    In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Larazotide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.